{"id":256,"date":"2024-08-15T02:28:29","date_gmt":"2024-08-15T02:28:29","guid":{"rendered":"http:\/\/60.204.213.123\/wordpress\/?page_id=256"},"modified":"2024-12-02T03:15:06","modified_gmt":"2024-12-02T03:15:06","slug":"%e5%b7%b2%e5%85%ac%e5%b8%83%e7%9a%84%e8%83%83%e7%99%8c%e6%8a%97%e5%8e%9f%e6%b8%85%e5%8d%95","status":"publish","type":"page","link":"https:\/\/www.guixiong.com.cn\/?page_id=256","title":{"rendered":"\u5df2\u516c\u5e03\u7684\u80c3\u764c\u6297\u539f\u6e05\u5355"},"content":{"rendered":"\n

\u80bf\u7624\u65b0\u6297\u539fmRNA\u75ab\u82d7\u5728\u52a0\u901f\u5ba1\u6279\u7684\u80cc\u666f\u4e0b\uff0c\u80bf\u7624\u7a81\u53d8\u6297\u539f\u7684\u7814\u7a76\u4ef7\u503c\u8d8a\u6765\u8d8a\u5927\uff0c\u4e3a\u6b64\uff0c\u6211\u4eec\u901a\u8fc7\u6587\u732e\u6316\u6398\uff0c\u4e3a\u8bfb\u8005\u6574\u7406\u4e86\u5404\u79cd\u80bf\u7624\u7684\u5df2\u9a8c\u8bc1\u80bf\u7624\u7a81\u53d8\u6297\u539f\u6e05\u5355\uff0c\u6211\u4eec\u5c06\u9646\u7eed\u53d1\u5e03<\/strong>\u3002<\/p>\n\n\n\n

\u4ee5\u4e0b\u662f\u76ee\u524d\u516c\u5e03\u7684\u80c3\u764c\u80bf\u7624\u6297\u539f\u80bd\u6e05\u5355\uff0c\u8be5\u6e05\u5355\u5747\u652f\u6301\u5b9a\u5236\u751f\u4ea7 (\u5b9a\u5236\u54a8\u8be2\u8bf7\u626b\u63cf\u672c\u9875\u53f3\u4fa7\u8054\u7cfb\u4eba\u4e8c\u7ef4\u7801)\u3002\u53ef\u5b9a\u5236\u751f\u4ea7\uff1a<\/p>\n\n\n\n

    \n
  1. \u68c0\u6d4b\u6216\u5206\u9009\u6297\u539f\u7279\u5f02\u6027T\u7ec6\u80de\u7684\u6d41\u5f0f\u8bd5\u5242\u3001\u78c1\u73e0\u5206\u9009\u8bd5\u5242<\/li>\n\n\n\n
  2. \u6784\u5efa\u6297\u539f\u80bd\u548cMHC\u590d\u5408\u7269\uff0c\u7528\u4e8e\u5408\u6210\u4eba\u5de5\u5448\u9012\u7269\uff0c\u4ece\u800c\u523a\u6fc0T\u7ec6\u80de\u589e\u6b96<\/li>\n<\/ol>\n\n\n\n

    \u80c3\u764c\u6297\u539f\u86cb\u767d\u7684\u6297\u539f\u80bd\u6570\u91cf\u5206\u5e03<\/h4>\n\n\n\n\n\n\n\t\n\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t\n\t
    Antigen Name<\/th>Description<\/th>Allele Name<\/th>paper<\/th>\n<\/tr>\n<\/thead>\n
    Protein E7<\/td>YMLDLQPETT<\/td>HLA-A*02:01<\/td>Occasional memory cytotoxic T-cell responses of patients with human papillomavirus type 16-positive cervical lesions against a human leukocyte antigen-A *0201-restricted E7-encoded epitope. Cancer Res 1996<\/td>\n<\/tr>\n
    Squamous cell carcinoma antigen recognized by T-cells 3<\/td>VYDYNCHVDL<\/td>HLA-A*24:02<\/td>Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004<\/td>\n<\/tr>\n
    Squamous cell carcinoma antigen recognized by T-cells 3<\/td>AYIDFEMKI<\/td>HLA-A*24:02<\/td>Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004<\/td>\n<\/tr>\n
    Tyrosine-protein kinase Lck<\/td>DYLRSVLEDF<\/td>HLA-A*24:02<\/td>Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004<\/td>\n<\/tr>\n
    Peptidyl-prolyl cis-trans isomerase B<\/td>VLEGMEVV<\/td>HLA-A2<\/td>Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004<\/td>\n<\/tr>\n
    lymphocyte-specific protein tyrosine kinase<\/td>KLVERLGAA<\/td>HLA-A2<\/td>Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004<\/td>\n<\/tr>\n
    Serine\/threonine-protein kinase WNK2<\/td>DLLSHAFFA<\/td>HLA-A2<\/td>Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004<\/td>\n<\/tr>\n
    Plasmanylethanolamine desaturase<\/td>RLQEWCSVI<\/td>HLA-A2<\/td>Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004<\/td>\n<\/tr>\n
    Dermatan-sulfate epimerase<\/td>DYSARWNEI<\/td>HLA-A*24:02<\/td>Immunological evaluation of vaccination with pre-designated peptides frequently selected as vaccine candidates in an individualized peptide vaccination regimen. Int J Oncol 2004<\/td>\n<\/tr>\n
    Prostatic acid phosphatase<\/td>LYCESVHNF<\/td>HLA-A*24:02<\/td>Prostatic acid phosphatase as a target molecule in specific immunotherapy for patients with nonprostate adenocarcinoma. J Immunother 2005<\/td>\n<\/tr>\n
    Claudin-18<\/td>YTFGAALFV<\/td>HLA-A*02:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n
    Claudin-18<\/td>GLLVSIFAL<\/td>HLA-A*02:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n
    Claudin-18<\/td>TLTSGIMFI<\/td>HLA-A*02:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n
    Claudin-18<\/td>GLPAMLQAV<\/td>HLA-A*02:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n
    Claudin-18<\/td>TLTSGIMFIV<\/td>HLA-A*02:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n
    Claudin-18<\/td>STGFGSNTK<\/td>HLA-A*11:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n
    Claudin-18<\/td>LLVSIFALK<\/td>HLA-A*11:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n
    Claudin-18<\/td>VAYKPGGFK<\/td>HLA-A*11:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n
    Claudin-18<\/td>SVAYKPGGFK<\/td>HLA-A*11:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n
    Claudin-18<\/td>HASGHSVAYK<\/td>HLA-A*11:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n
    Claudin-18<\/td>GLLVSIFALK<\/td>HLA-A*11:01<\/td>Antigen-Specific T Cell Immunotherapy Targeting Claudin18.2 in Gastric Cancer. Cancers (Basel) 2022<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n\n\n\n\n

    <\/p>\n\n\n\n

    \n

    \u91cd\u70b9\u8bf4\u660e\uff1aClaudin-18\u4f5c\u4e3a\u9776\u70b9\u7684\u5728\u7814\u836f\u7269\u670970\u591a\u79cd\u8fdb\u5165\u4e34\u5e8a\u8bd5\u9a8c\uff0c\u8be5\u9776\u70b9\u662f\u80c3\u764c\u9886\u57df\u7684\u70ed\u70b9\u7814\u53d1\u9886\u57df\u3002\u5176\u4e2d\uff0cCLDN18.2\u662f\u7814\u7a76\u6700\u4e3a\u900f\u5f7b\u7684CLDN18\u86cb\u767d\u6210\u5458\u3002<\/p>\n\n\n\n

    CLDN18.2\u901a\u5e38\u5b58\u5728\u4e8e\u80c3\u9ecf\u819c\u7ec6\u80de\u7684\u7d27\u5bc6\u8fde\u63a5\u5904\uff0c\u7ef4\u6301\u80c3\u7c98\u819c\u7684\u5c4f\u969c\u529f\u80fd\uff0c\u9632\u6b62\u80c3\u9178\u7684H+\u901a\u8fc7\u7ec6\u80de\u65c1\u8def\u9014\u5f84\u6e17\u900f\u3002CLDN18.2\u5728\u6b63\u5e38\u7ec4\u7ec7\u4e2d\u8868\u8fbe\u6709\u9650\uff0c\u800c\u5728\u591a\u79cd\u6076\u6027\u80bf\u7624\u53d1\u5c55\u4e2d\u5f02\u5e38\u8868\u8fbe\uff0c\u5982\u80c3\u764c\/\u80c3\u98df\u7ba1\u4ea4\u754c\u5904\u764c\u75c7\uff08GC\/GEJ\uff09\u3001\u4e73\u817a\u764c\u3001\u7ed3\u80a0\u764c\u3001\u809d\u764c\u3001\u5934\u9888\u764c\u3001\u652f\u6c14\u7ba1\u764c\u548c\u975e\u5c0f\u7ec6\u80de\u80ba\u764c<\/strong>\u3002CLDN18.2\u53c2\u4e0e\u80bf\u7624\u7ec6\u80de\u7684\u589e\u6b96\u3001\u5206\u5316\u548c\u8fc1\u79fb\u3002\u764c\u7ec4\u7ec7\u7684\u7d27\u5bc6\u8fde\u63a5\u88ab\u7834\u574f\uff0c\u5bfc\u81f4CLDN18.2\u7ed3\u5408\u8868\u4f4d\u66b4\u9732\u51fa\u6765\u3002<\/p>\n\n\n\n

    \u8fd9\u4f7f\u9776\u5411\u7684\u5927\u5206\u5b50\u836f\uff0c\u6bd4\u5982\u6297\u4f53\u836f\u7269\uff0c\u751a\u81f3CAR-T\u7ec6\u80de\u6cbb\u7597\u836f\u7269\u66f4\u6613\u4e0e\u80bf\u7624\u90e8\u4f4d\u7684CLDN18.2\u7ed3\u5408\uff0c\u800c\u4e0d\u4e0e\u6b63\u5e38\u7ec4\u7ec7\u4e2d\u7684CLDN18.2\u7ed3\u5408\uff0c\u51cf\u5c0f\u6bd2\u526f\u4f5c\u7528\u3002<\/p>\n<\/blockquote>\n\n\n\n

    \u80c3\u7624\u6297\u539f\u6e05\u5355\u4f7f\u7528\u65b9\u6cd5\uff1a<\/strong><\/h3>\n\n\n\n

    \u80bf\u7624\u5fae\u73af\u5883\u7814\u7a76\uff1a<\/strong><\/h4>\n\n\n\n

    \u68c0\u6d4b\u80bf\u7624\u6d78\u6da6\u6dcb\u5df4\u7ec6\u80de\u4e2d\uff0c\u80bf\u7624\u6297\u539f\u7279\u5f02\u6027\u6dcb\u5df4\u7ec6\u80de\u7684\u6570\u91cf\u5b9e\u73b0\u3002\u5177\u4f53\u65b9\u5f0f\u662f\uff1a\u6839\u636e\u6e05\u5355\u5185\u5bb9\uff0c\u5c06\u6297\u539f\u80bd\u548cHLA\u5408\u6210\u4e3a\u6297\u539f\u80bdMHC\u590d\u5408\u7269\u8367\u5149\u56db\u805a\u4f53\uff0c\u901a\u8fc7\u6d41\u5f0f\u7ec6\u80de\u68c0\u6d4b\u65b9\u6cd5\uff0c\u68c0\u6d4b\u80bf\u7624\u6d78\u6da6\u6dcb\u5df4\u7ec6\u80de\u7684\u542b\u91cf\u3002<\/p>\n\n\n\n

    \u80bf\u7624\u514d\u75ab\u7ec6\u80de\u7684\u5168\u8eab\u5206\u5e03\uff1a<\/strong><\/h4>\n\n\n\n

    \u901a\u8fc7\u68c0\u6d4b\u5916\u5468\u8840\u4e2d\u80bf\u7624\u6297\u539f\u7279\u5f02\u6027\u6dcb\u5df4\u7ec6\u80de\u7684\u6570\u91cf\u5b9e\u73b0\u3002\u5177\u4f53\u65b9\u6cd5\u540c\u4e0a\u3002<\/p>\n\n\n\n

    \u8fc7\u7ee7\u6027\u80bf\u7624\u514d\u75ab\u7ec6\u80de\u6cbb\u7597\uff1a<\/strong><\/h4>\n\n\n\n

    \u4f7f\u7528\u6e05\u5355\u4e2d\u6297\u539f\u80bd\uff0c\u523a\u6fc0\u6dcb\u5df4\u7ec6\u80de\uff0c\u800c\u540e\u4f7f\u7528\u6297\u539f\u80bdMHC\u590d\u5408\u7269\u8367\u5149\u56db\u805a\u4f53\u6216\u78c1\u73e0\u56db\u805a\u4f53\uff0c\u901a\u8fc7\u6d41\u5f0f\u5206\u9009\u6216\u78c1\u73e0\u5206\u9009\u7ec6\u80de\uff0c\u7ecf\u4f53\u5916\u7ec6\u80de\u589e\u6b96\u540e\uff0c\u56de\u8f93\u4f53\u5185\uff0c\u8bc4\u4f30\u80bf\u7624\u6291\u5236\u6548\u679c\u3002<\/p>\n\n\n\n

    \u80bf\u7624\u6297\u539f\u7279\u5f02\u6027TCR\u6d4b\u5e8f\uff1a<\/strong><\/h4>\n\n\n\n

    \u901a\u8fc7\u80bf\u7624\u6d78\u6da6\u6dcb\u5df4\u7ec6\u80de\u3001\u6216\u5916\u5468\u8840\u6dcb\u5df4\u7ec6\u80de\uff0c\u901a\u8fc7\u5206\u9009\u540e\u8fdb\u884c\u5355\u7ec6\u80deTCR\u6d4b\u5e8f\uff0c\u83b7\u5f97\u6297\u539f\u7279\u5f02\u6027T\u7ec6\u80de\u7684TCR\u5e8f\u5217\uff0c\u8fdb\u4e00\u6b65\u8fdb\u884cTCR-T\u7597\u6cd5\u7814\u7a76\u3002<\/p>\n\n\n\n

    \u80bf\u7624\u75ab\u82d7\u7247\u6bb5\u7b5b\u9009\uff1a<\/strong><\/h4>\n\n\n\n

    \u7efc\u5408\u4e0a\u8ff0\u8fc7\u7a0b\uff0c\u83b7\u5f97\u5177\u6709\u6fc0\u6d3bT\u7ec6\u80de\u6740\u4f24\u80bf\u7624\u7ec6\u80de\u7684\u7ecf\u9a8c\u8bc1\u6297\u539f\u80bdMHC\u590d\u5408\u7269\uff0c\u7528\u4e8e\u80bf\u7624\u75ab\u82d7\u6784\u5efa\u3002<\/p>\n

    Views: 8<\/p>","protected":false},"excerpt":{"rendered":"

    \u80bf\u7624\u65b0\u6297\u539fmRNA\u75ab\u82d7\u5728\u52a0\u901f\u5ba1\u6279\u7684\u80cc\u666f\u4e0b\uff0c\u80bf\u7624\u7a81\u53d8\u6297\u539f\u7684\u7814\u7a76\u4ef7\u503c\u8d8a\u6765\u8d8a\u5927\uff0c\u4e3a\u6b64\uff0c\u6211\u4eec\u901a\u8fc7\u6587\u732e\u6316\u6398\uff0c\u4e3a\u8bfb\u8005\u6574\u7406\u4e86…<\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_kadence_starter_templates_imported_post":false,"_kad_post_transparent":"","_kad_post_title":"","_kad_post_layout":"","_kad_post_sidebar_id":"","_kad_post_content_style":"","_kad_post_vertical_padding":"","_kad_post_feature":"","_kad_post_feature_position":"","_kad_post_header":false,"_kad_post_footer":false,"_kad_post_classname":"","footnotes":""},"class_list":["post-256","page","type-page","status-publish","hentry"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/256","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=256"}],"version-history":[{"count":2,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/256\/revisions"}],"predecessor-version":[{"id":615,"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=\/wp\/v2\/pages\/256\/revisions\/615"}],"wp:attachment":[{"href":"https:\/\/www.guixiong.com.cn\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=256"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}